Shattuck Labs, Inc. (STTK) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 40 days, typically, give or take 19 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Nov 5, 2026before open 36 8-K
Q2 FY2026Tue, Aug 11, 2026before open 42 8-K
Q1 FY2026Thu, May 7, 2026before open 37 8-K
Q4 FY2025Thu, Mar 5, 2026before open 64 8-K
Q3 FY2025Thu, Nov 6, 2025after close 37 8-K
Q2 FY2025Thu, Aug 14, 2025before open 45 8-K
Q1 FY2025Thu, May 1, 2025after close 31 8-K
Q4 FY2024Thu, Mar 27, 2025before open 86 8-K

What they guided beta

Q3 FY2026 "Document Exhibit 99.1 Shattuck Labs Reports Third Quarter 2026 Financial Results and Recent Business Highlights – Initiated the RECEPTIVE-CD1 Phase 2b clinical trial of SL-325 in Crohn’s disease; 12-week induction data expected in the first half of 2028 – – Announced RECEPTIVE-HS1 Phase 2 clinical trial of SL-325 in hidradenitis suppurativa; trial initiation expected in the fourth quarter of 2026 – – Presented preclinical data for SL-846 at UEG Week 2026, including data from a chronic toxicology study in non-human primates – AUSTIN, TX and DURHAM, NC, Nov. 05, 2026 -- Shattuck Labs, Inc. (Shat" exhibit
Q3 FY2026 ""In addition, SL-846 has demonstrated a compelling profile in preclinical studies, and we expect to share initial Phase 1 clinical data for what we expect to be a first-in-class DR3 by IL-23 receptor blocking antibody in 2027." DR3 Program Development in 2026 Shattuck is advancing a pipeline of DR3-targeted monoclonal and bispecific antibody product candidates for the treatment of inflammatory and immune-mediated diseases." exhibit
Q3 FY2026 "These data are expected in the first half of 2028." exhibit
Q3 FY2026 "Announced plans to initiate the RECEPTIVE-HS1 Phase 2 clinical trial of SL-325 in patients with moderate to severe hidradenitis suppurativa, with trial initiation expected in the fourth quarter of 2026." exhibit
Q3 FY2026 "Primary endpoint is HiSCR50 response at Week 16, with data expected in the first half of 2028." exhibit
Q2 FY2026 "Document Exhibit 99.1 Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights – Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A binding, potentially enabling prolonged dosing intervals – – RECEPTIVE-CD1 Phase 2b clinical trial of SL-325 in patients with Crohn’s disease expected to initiate in the third quarter of 2026 – – Announced lead DR3 x IL-23 receptor blocking, half-life extended bispecific antibody product candidate, SL-846, with " exhibit
Q2 FY2026 ""The RECEPTIVE-CD1 Phase 2b clinical trial in Crohn’s disease is on track to initiate in the third quarter, and is designed to establish the efficacy profile of SL-325 across three dose levels, both at induction and at maintenance time points." exhibit
Q2 FY2026 "RECEPTIVE-CD1 Phase 2b clinical trial of SL-325 in patients with moderately-to-severely active Crohn's disease is expected to initiate in the third quarter of 2026." exhibit
Q2 FY2026 "These data are expected in the first half of 2028." exhibit
Q2 FY2026 "Preclinical data for SL-846, including safety, pharmacokinetics, and receptor occupancy from the ongoing GLP toxicology study are expected to be presented in a poster at UEG Week, to be held October 17-20, 2026." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/STTK
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/STTK

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

STTK earnings date badge

HTML

<a href="https://veritasdata.dev/company/STTK/"><img src="https://veritasdata.dev/embed/STTK.svg" alt="STTK earnings date" width="240" height="56"></a>

Markdown

[![STTK earnings date](https://veritasdata.dev/embed/STTK.svg)](https://veritasdata.dev/company/STTK/)

Script

<script async src="https://veritasdata.dev/embed/STTK.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/STTK"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.